CaP CURE 2002 Review

Contents

From the Chairman 4

From the CEO 6

Year in Review 8

Funding Research 12

Collaboration 22

Raising Money 25

and Awareness

Research Awards 32

Leadership 38

Dr. Ward “Trip” Casscells

Diagnosed with prostate cancer at age 48.

Patient profile on page 10.

William Clapp

Diagnosed with prostate cancer at age 63.

Patient profile on page 20.

Professor Gerald Haslam

Diagnosed with prostate cancer at age 60.

Patient profile on page 30.

Prostate canceraffects everyone,

not just men.Wh en a man gets pro s t a te cancer, it ch a n ge s

his life. And that affects everyone close to him — friends

and family, men and women. That’s why on our cover we

have shown the faces of many people — fathers, mothers,

brothers, sisters, children, physicians, scientists, and others.

They are as committed as we are to finding better treat-

ments and, eventually, a cure.

Family histories and genes may hold

the key to solving part of the prostate

cancer puzzle.

When a man gets prostate cancer, it affects

everyone close to him.

Stu a rt Hol d en ,M . D. , PCF medical dire cto r,

is surrounded by PCF competitive awards

applications.The PCF originated a

“fast-track” grant-application process

so researchers could devote their time to

advancing science rather than pleading

for funds and completing seemingly

endless forms.

Dr. Andrew von Eschenbach, director of

the National Cancer Institute,is the only

cancer survivor ever to hold this office.

Dr. von Eschenbach has contributed to the

PCF’s scientific mission since its inception.

A man is one-third more likelyto get pro s t a te cancer than a woman is to get breast cancer.

Prostate cancer is the most common non-skin

cancer in America, striking 220,000 new men each year.

There is one new case every 2 ½ minutes.

As baby boomer men reach the target zone for

prostate cancer, beginning at age 50, the number of new

cases is projected to increase dramatically. By 2015, there

will be more than 300,000 new prostate cancer cases each

year, a 50% increase.

3

The PCF hosted its 2001 New York Dinner,

a star-studded, fund-raising event at the

Waldorf-Astoria Hotel. Hosted by Whoopi

Goldberg, the dinner honored the Mack

brothers: Bill, David, Earle and Fred.

From left: Debbie Black, Ann Tenenbaum,

Tom Lee, Rupert Murdoch, Whoopi

Goldberg, Joe Torre, Mickey Tarnopol,

Mike Milken and David Foster.

Increasing Public Awareness

Recent scientific advances,

many driven by Prostate Cancer

Foundation-funded researchers,

are more promising than ever.

We changed our name from

CaP CURE to the Prostate Cancer

Foundation to increase public

awareness of our role in harnessing

society’s resources to defeat this

deadly disease.

The need remains great. Your help

has never been more important.

Since 1993, the ProstateCancer Foundation has:

• Raised approximately $200 million.

• Funded more than 1,100 critical

research projects in 100 research

centers around the world.

• Recruited talented scientists.

• Helped to increase annual govern-

ment funding from $25 million to

more than $500 million.

• Greatly increased public awareness,

which encouraged millions more

men to be tested.

• Helped to increase the number

of prostate cancer drugs under

development by 50%.

4

If you’re old enough to remember

the day President Kennedy was

assassinated, you’ll never forget

where you were and what you were

doing. Six years later, you were

prob a bly watching TV and rem em ber

who watched with you when men

first landed on the Moon. More

recently, the tragedy of September

11th is undoubtedly seared in your

memory. And if you, like nearly

one and a half million Americans

each year, ever heard the words

“You have cancer,” you’ll always

remember the moment.

Few families avoid cancer. Thirty-

one years ago, my mother-in-law

learned she had breast cancer. A few

years later, my father was told he

had melanoma. Eventually, this

disease claimed 10 members of my

family. So cancer isn’t something I

think about once in a while — it’s

very immediate, very personal,

and in my thoughts constantly. It

changed the course of my life long

before I was diagn o s ed . It’s one of t h e

reasons my brother and I formalized

our philanthropy in 1982 by estab-

lishing the Milken Family Medical

Foundation with a commitment to

advancing medical research. We

established a program of awards

for young cancer researchers so

they could afford to continue their

laboratory investigations.

Twenty-one years separated my

mother-in-law’s diagnosis from the

day in 1993 when my doctor told me,

“You have prostate cancer.” Over

those two decades, my conversations

with hundreds of doctors — both as

a philanthropist and as a patient

advocate — made me feel about as

well informed as a layman can be on

the complex topic of cancer. So the

shock of learning I had cancer was

compounded by learning how little

information was available about

prostate cancer. Not only was my

prognosis poor — the cancer had

escaped my prostate and was too

advanced for surgery — but informa-

tion about my medical options was

A Passionate Pursuit

Gen. Norman Schwarzkopf joined

Mike Milken in 1998 to address several

hundred th ousand march ers on the Ma ll in

Wa s h i n g ton D. C . at THE MARCH: Coming

Together to Conquer Cancer. Mike and PCF

honorary board member Sydney Kimmel

h el ped orga n i ze the even t . Gen .S chwa r z kop f

is a prostate cancer survivor.

Cancer isn’t something I think

about once in a while — it’s very

immediate, very personal, and

in my thoughts constantly.

5

scarce. In 1993,most experts

thought the prostate cancer death

rate would rise sharply over the

next decade as baby boomers aged.

Yet with little financial support or

public interest, prostate cancer

re s e a rch was con s i dered a back w a ter

of medicine.

The Prostate Cancer Foundation

( form erly CaP CURE) was establ i s h ed

with more in mind than accelerating

a cure for prostate cancer. From the

beginning, we aspired to change

the face of cancer research and to

produ ce re sults that could help peop l e

suffering from a broad range of

serious diseases. We never saw the

process as a zero-sum game where

increased funding for one disease

diminished support for others.

Rather, it has always been one of

our key goals to increase the size of

the research pie in ways that would

ben efit the gre a test nu m ber of peop l e .

The changes that the Prostate

Cancer Foundation has helped

bring about over the past decade are

documented in this Annual Report.

But the most important change is

in the number of prostate cancer

deaths, which have been kept well

below the pessimistic projections of

1993. Also, because of better treat-

ments, survivors enjoy an improved

quality of life. Everyone who has

worked so hard in this effort can

take a large measure of satisfaction

from the results. But despite all that

has been achieved, there’s concern

about the future. Some 70 million

Americans are reaching the age

when the rate of cancers begins to

rise quickly. As Prostate Cancer

Foundation Vice Ch a i rman and

CEO Leslie Mi ch el s on explains

on pages 6– 7,the number of new

prostate cancer diagnoses will soon

grow by as much as 50% if nothing

else changes.

This Annual Report is both a

review of past progress and an

appeal for your involvement in our

continuing effort. The Prostate

Cancer Foundation is the world’s

largest philanthropic source of

support for prostate cancer studies.

We ensure that the scientists

working at the very edge of science

have the resources they need. They

share our sense of urgency, racing

against time to eliminate a disease

that currently takes an American life

every 18 minutes.

We need your support to fast-

forw a rd this qu e s t . I bel i eve ferven t ly

that the goal is attainable when

brilliant, dedicated researchers and

passionate advocates come together

with the ri ght re s o u rce s . We just want

to get there sooner rather than later.

Thank you for helping. Thank you

for expressing your passion for life!

Michael Milken

Founder and Chairman

PCF founder and chairman Mike Milken

(left) and Richard Pazdur, M.D.,director of

the FDA’s division of oncology drug products,

listen to Andrew von Eschenbach,M.D.,

director of the National Cancer Institute

(NCI), during the Prostate Cancer

Foundation’s 2002 Scientific Retreat in

Houston Astros owner Drayton McLane

joined Mike Milken in the fight against

pro s t a te cancer du ring the Pro s t a te Cancer

Foundation’s CaP CURE Home Run

Challenge. Each year, Major League

Baseball,the Major League Baseball

Players Association,the Prostate Cancer

Foundation,and fans nationwide raise

money to fund prostate cancer research

based on home runs hit in 60 ball games

during the week before Father’s Day.

Washington, D.C. Both the Prostate Cancer

Foundation and von Eschenbach advocated

a systems approach to cancer research and

the search for a cure, requiring a close

working relationship between the NCI

and academic and private researchers.

6

The National Cancer Institute’s 2003

projections unfortunately confirm

what our epidemiologists predict.

This ye a r, the nu m ber of n ew pro s t a te

cancer cases in the U.S. will increase

to 220,000. Prostate cancer is now

the most common non-skin cancer

in Am eri c a . It accounts for on e - t h i rd

of a ll major cancers in men — more

than twice the next most common.

One in six men will get cancer in

their lifetime.

It gets worse. As the baby boomer

m en re ach the target age for pro s t a te

cancer, beginning at age 50, the

annual incidence will increase to

300,000 and the annual death rate

will reach 50,000 by 2015. Prostate

cancer is not only distressingly

common; it is also the cancer with

the largest expected increase in the

next decade. Unfortunately, few

people realize the significance of

this disease.

For the past decade, the Prostate

Cancer Foundation has been

working tirelessly to accelerate

the discovery of better treatments

and a cure to prevent this tragedy.

When we began, efforts to find a

cure were at a standstill. Scientists

had few sources of funding and

little reason to engage in prostate

cancer research. Federal funding

was minimal and no ph a rm aceuti c a l

or biotech companies were focused

on it. Men facing prostate cancer

had few good weapons to fight the

disease and little hope that new

treatments would become available

before the disease took its toll.

The Prostate Cancer Foundation

has become the world’s largest

philanthropic source of funding

for prostate cancer research. We

are focused on finding a cure.

With generous support from our

many committed donors, we have

supported some 1,100 research

projects in 100 research centers

around the world since 1993. We

invest 78 cents of every dollar we

raise on medical and scientific

research. That is more than three

times the avera ge amount spent

by the other major health-care

philanthropies.

Letter from the CEO

Age-Specific Probability of Diagnosis of Prostate Cancer

Prostate cancer attacks with remarkable aggression beginning at age 50.

0%

50%

100%

Other Major Disease

Philanthropies

22%

78%

Prostate Cancer

Foundation

Percentage of Funds

Dedicated to Scientific

and Medical Research

7

In the past five years, the number

of prostate cancer drugs under

development has increased 50%.

Federal and corporate funding of

research has increased dramatically

and new experimental strategies

now offer the promise of turning

pro s t a te cancer from a life - t h re a ten i n g

disease into a treatable disorder. We

have been there every step of the

way, prodding government policy

makers to provide more resources,

and ign i ting an ex p l o s i on of s c i en ti f i c

inquiry by researchers in academic

centers, biotechnology firms, and

pharmaceutical companies. We

work closely with these scientists

to accelerate the development of

new treatments.

While we wi ll con ti nue our histori c a l

efforts, now we must also:

• Identify and act on specific oppor-

tunities to accelerate the biomedical

research and development process

in prostate cancer;

• Im prove the ef f i c i ency and ef fec-

tiven e s s of work funded by others;

• Infuse the entire system with a

greater sense of urgency and

accountability; and

• Increase our support for bold,

high-impact initiatives.

We face special challenges in our

effort to harness more of society’s

resources to fight prostate cancer,

however. First and foremost,there

is little public recognition of the

gravity of this disease. Few people

realize that a man is one-third more

likely to get prostate cancer than a

woman is to get breast cancer.

Second, this disease attacks men,

a tough group to get motivated to

prevent a future health problem.

Many men characteristically refuse

to confront health issues until they

are compelled to do so and are

particularly reluctant to deal with

sensitive issues related to sexual

health. To address these challenges,

we are launching communications

and other programs to raise public

awareness and educate men and

their families.

Although the progress in finding

better treatments has been dramatic,

the impending increase in incidence

makes the need greater than ever.

Fortunately, recent advances in

science have made the opportunities

greater than ever as well. With your

support, we will be able to pursue

more of these opportunities and

hasten the day when prostate cancer

is merely a sad memory.

Leslie D. Michelson

Vice Chairman and CEO

New Cancer Cases (in thousands)

Prostate cancer is the most common and most rapidly increasing cancer.

8

Prostate Cancer Foundation

Year in Review

PCF volunteers Ferne Milken, Sybil Gordon

and Elly Levin proudly wear their “CURE”

hats while putting together information

packets about prostate cancer. PCF board member Mickey Tarnopol

and his wife, Lynne, were the benefit co-

chairs for the 2001 New York Dinner at

the Waldorf-Astoria Hotel in New York.

The Tarnopols helped make the PCF

dinner a great success.

Members of the PCF Therapy Consortium

meet regularly to address major issues that

impede progress in clinical development of

new treatments.The Therapy Consortium

comprises eight centers of excellence where

leading medical oncol o gists wo rk on improved

prostate cancer treatments.

Since its inception in 1993, the

Prostate Cancer Foundation (PCF) has become a model for

other philanthropies, simplifying and speeding the grant-

application process, organizing centers of excellence, bringing

toget h er ex pertise from all corn ers of the scien tific com mu n i ty,

and encouraging close collaboration among research leaders.

The PCF has helped to nurture the best talent in medical

research institutions around the world and broken down

b a rri ers bet ween the labora tory and the cl i n i c , h elping pati en t s

receive state-of-the-art treatments sooner. Our efforts have

contributed to a 50% increase in the number of prostate

cancer drugs under development in the past five years and a

20-fold increase in government funding of prostate cancer

research over the past 10 years.

9

Since 1996,the PCF has partnered with

Major League Baseball and the Major

League Baseball Players Association in the

Prostate Cancer Foundation CaP CURE

Home Run Challenge. With support from

Major League teams, coaches, players,

managers and umpires,the HRC has

ra i sed more than $18 million for pro s t a te

cancer research.

Safeway, one of the largest food retailers in

North America, partnered with the PCF

for a third year in a row to raise money

and awareness. Steve Burd,Safeway’s

president and chief executive officer, led a

company-wide campaign that include d

po i n t - of - pu rch a se pro m otions at more than

The Prostate Cancer Foundation is

the world’s largest philanthropy

supporting prostate cancer research.

The PCF has earned wide-

spread respect by:

• Attracting and aggregating a

critical mass of talented and

dedicated scientists conducting

basic and translational research;

• Creating a rapid-response, risk-

taking funding system that reduces

bureaucracy and accelerates research

while maintaining scientific rigor;

• Raising awareness of the need

for more prostate cancer research

funding by government agencies

that have increased appropriations

from roughly $25 million in 1993

to more than $500 million today;

• Forming a Therapy Consortium

of eight leading prostate cancer

research centers;

• Creating the largest database of

f a m i ly - clu s tered pro s t a te cancer cases;

• Creating a tissue bank and animal

model network; and

• Fostering collaboration among aca-

demic, corporate, and governmental

researchers through the annual PCF

Scientific Retreat and other forums.

15,000 checkout stands in all 1,600

Safeway stores in the U.S. Employees

also participated in internal fundraising

drives to boost proceeds. In 2003, the

campaign raised more than $2.5 million

for prostate cancer research.

10

Dr. Ward “Trip” Casscells

Diagnosed with prostate

cancer at age 48.

Dr. Ward “Trip” Casscells, an inter-

nationally recognized cardiologist,

has spent his career developing

better treatments for and helping

patients survive heart disease.

One night in 2001,he woke with an

unusual pain in his stomach. Lying

in bed, he examined his abdomen

and was stu n n ed to find an abn orm a l

growth.Days later, an MRI revealed

metastatic prostate cancer. His prog-

nosis: 18 months to live. He was 48,

at the peak of a successful medical

career, a husband and the father o f

three young children.“I wanted to

scream or cry, but I didn’t have

time,” Dr. Casscells remembers.“I

envisioned writing letters to my

children and making a videotape

for them to remember me. It was

overwhelming.”

Dr. Casscells immersed himself in

the available state-of-the-art treat-

ments for his condition. He and his

wi fe , Rox a n n e ,s aw Drs . Ch ri s toph er

Logothetis,a medical oncologist,

and Andrew von Eschenbach, a

urologist who has become director

of the National Cancer Institute, at

M. D. Anderson Cancer Center.

“We’ ll get you fixed up,” D r. Logo t h eti s

said. He prescribed an innovative

and aggressive regimen of hormones

and chemotherapy intended to treat

advanced prostate cancer. After just

one day, Dr. Casscells felt better.

“When the Prostate Cancer

Foundation funded the develop-

ment of this treatment program,

chemotherapy for prostate cancer

was regarded as a poison unfit for

humankind,” says Dr. Logothetis.

As recently as three years ago, Dr.

Casscells’ only option would have

been single therapy with hormones

and the prognosis would have been

• Prostate cancer is the most com-

mon non-skin cancer in America,

striking 220,000 men in 2003.

• Prostate cancer attacks aggressively

beginning at age 50.

• The number of new cases per year

is projected to increase by 50% to

300,000 by 2015.

gri m .P C F- f u n ded re s e a rch progra m s

like this have shown that integrated

treatment approaches can help

keep prostate cancer at bay for years.

Oncologists are learning to use these

revo luti on a ry therapies wi s ely, g u i ded

by biochemical markers that help

monitor their effectiveness.

The markers are “predictive of

relapse, and can guide the selection

of f utu re thera py,” s ays Dr. Logo t h eti s .

“When we needed funding to initi-

ate this research, only the PCF was

willing to step forward.”

Since completing this combination

of chemotherapy and hormones

two years ago, Dr. Casscells’ disease

remains in remission. Today, he

foresees a longer future and hopes

to see his children graduate from

high school and reach other mile-

stones. He hasn’t sat down yet to

write anything to them.“I’ve been

given my life back,” he says.“I don’t

know how the story turns out.”

He was 48,at the peak of a successful

medical career, a husband and the father

of three young children.“I envisioned

writing letters to my children and making

a videotape for them to remember me.

It was overwhelming.”

Patient Profile

“I wanted toscream or cry, but I

didn’t have time.”

12

• Funded the development of vaccines

that harness the body’s immune

s ys tem to kill pro s t a te cancer cell s ;a n d

• Funded gene therapy approaches

to selectively eliminate prostate

cancer cells.

PCF grant funding has led directly

to many adva n ces in com preh en d i n g

the underlying mechanisms of

prostate cancer — advances that

have or will lead to better treat-

ments of prostate cancer:

• Identification of the genetic changes

that might cause cells in the prostate

to become cancerous;

• Stopping the production or func-

tion of growth factors that cancer

cells need to continue growing;

• Interfering with the development of

blood vessels that feed nutrients to

cancer cells;

• Determination of the structure of

the androgen receptor, the molecule

that drives the growth of prostate

cells,and the discovery of ways to

inhibit it;

The PCF Funds High-

Potential Research

Just as venture capital firms advance

technology by funding promising

commercial strategies and products,

the Prostate Cancer Foundation

fo ll ows a similar model by su pporti n g

innovative,early-stage research

projects that offer the greatest hope.

These high - i m p act re s e a rch proj ect s ,

many of which would not have

been funded without our support,

include clinical research to evaluate

new drugs,innovative treatment

strategies for prostate cancer, and

basic science research to understand

the biology of prostate cancer. As

part of its efforts to move drugs into

the clinic quickly, the PCF has:

• Funded the discovery and/or early

clinical devel opm ent of PSMA mon o-

clonal antibodies, Velcade, Zometa,

Atrasentan,and Omnitarg;

Funding Research

The PCF has funded more than

1,100 crucial research projects

in 100 research centers around

the world.

Alaska Senator Ted Stevens,a cancer

survivor and chairman of the U.S. S en a te

Appropri a tions Co m m i t te e , has be en one of

the earliest su ppo rters of the PCF and its

mission to find better treatments and a

cure for prostate cancer. Senator Stevens

has been one of the strongest congressional

advocates for increased cancer funding.

All 30 Major League Baseball teams provide

support for the Prostate Cancer Foundation

CaP CURE Home Run Challenge in many

ways.Clubs host pre-game ceremonies, run

pu blic servi ce annou n cem en t s ,d o n a te ti cket s ,

place blue ribbons on the field and support

the player representatives. Owners, coaches,

executives,umpires, trainers, groundskeepers,

and front office staff are behind the cause by

h o s ting spe cial events en d o rsing and pro m oti n g

the Home Run Challenge.

13

• Identification of prostate cell surface

markers that can be targeted to

destroy cancerous cells; and

• Development of analytical methods

that identify the proteins in blood

or the prostate that correlate to

treatment effect or behavior of the

cancer cell — also known as

proteomic pattern recognition.

Competitive Awards

The PCF originated a “fast-track”

grant-application process so

researchers could devote their time

to advancing science rather than

pleading for funds and completing

seemingly endless forms. The time

from submission of a request to

money-in-hand was reduced to 90

days. The reporting of results was

reduced to a six-month progress

report letter and a presentation at

the annual PCF Scientific Retreat.

PCF competitive research awards

have resulted in a dramatic increase

in the number of talented physicians

Mike Milken and Baseball Hall of Fame

manager Tommy Lasorda look on as News

Corp. chairman Rupert Murdoch,a prostate

cancer survivor, leads a “wave” at Dodger

Stadium to celebrate another home run that

raised money for prostate cancer research

during the Prostate Cancer Foundation

CaP CURE Home Run Challenge.

(Photo courtesy of the Los Angeles Times)

Bob Dole, former Senate Majority Leader

and presidential candidate, told attendees

at the 2002 PCF Sci en tific Retreat about his

experience as a prostate cancer survivor.

Nobel laureates in medicine and science

debated our biological and scientific

future at the 2003 Milken Institute Global

Co n feren ce . From left: Syd n ey Bren n er, wh o

received his Nobel Prize for his discoveries

concerning genetic regulation of organ

development and programmed cell death;

Steven Chu, who received his Nobel Prize

for the development of methods to cool and

trap atoms with laser light; Mike Milken,

chairman and founder of the PCF and the

Milken Institute; and Joshua Lederberg,

who received his Nobel Prize for discoveries

concerning genetic recombination.

and scientists who are conducting

prostate cancer research. In order

to attract new talent, nearly half of

these PCF-funded awards are earned

by qualified researchers who have

never before received PCF funds.

Leaps of Faith Lead to

Meaningful Results

The impact of PCF-funded

programs is realized when they

demonstrate great promise and

receive funding from bi o tech n o l ogy

and ph a rm aceutical companies

or from government research

a gen c i e s . Examples of PCF su cce s s

stories include:

Velcade Chemist Julian Adams had

lost internal support at his company

for ongoing research on a com-

pound named PS-341 (Velcade)

and the project was about to b e

terminated. He persuaded the PCF

to fund a Phase I clinical trial of

Velcade. The results of this study

were encouraging. As a result,

Millennium Pharmaceuticals, a

The PCF cuts through the red

tape of research funding. PCF

grant applicants are limited to

five-page submissions and get a

response within 60 days… with

funds delivered in 90 days.

14

major biotech firm, acquired the

company that owned Velcade and

invested millions of dollars to

continue development of the drug.

In 2003, the FDA approved Velcade

for the treatment of multiple

myeloma — a cancer of the blood.

There is significant interest in com-

bining Velcade with chemotherapy

for advanced prostate cancer and

s tudies of this tre a tm ent com bi n a ti on

are currently in progress. Further

studies in advanced prostate cancer

and other solid tumors continue.

Zometa The PCF funded medical

oncologist Matthew Smith, M.D.,

Ph.D., of Massachusetts General

Hospital to conduct a series of

clinical studies at Harvard Medical

School on the use of bisphospho-

nates in the treatment of advanced

prostate cancer. The first clinical

trial con du cted by Dr. Smith foc u s ed

on the use of a bisphosphonate

known as Aredia (pamidronate)

for the prevention of bone loss

in patients undergoing androgen

deprivation therapy (ADT).

An estimated one million men

diagnosed with prostate cancer are

undergoing ADT with loss of bone

density (osteoporosis) as a major

side effect. The results of this study

were published in the New England

Journal of Medicine in September

2001 and showed that Aredia mini-

mizes bone loss and associated

skeletal-related events in men

undergoing ADT.

Based on these encouraging results,

Novartis,the seventh largest phar-

maceutical company in the world

and the manufacturer of Aredia,

committed significant resources to

the development of a more potent

bisphosphonate known as Zometa

(zolendronate) to prevent bone loss

and skeletal-related events in men

with pro s t a te cancer under going A D T.

PCF-funded research results

in effective treatments to

patients living with advanced

prostate cancer.

Leroy Hood,M.D., Ph.D., president,director

and professor at the Institute for Systems

Biology, was the architect of the PCF Gene

and Family Studies Consortium, which

has created the largest repository of genetic

samples from families with multiple indi vid-

uals affected by prostate cancer. The goal of

the consortium is to identify genes that cause

prostate cancer.

Home Run Challenge Goodwill Ambassador

and Baseball Hall of Fame manager, Tommy

Lasorda,stands between New York Yankees

manager Joe Torre (left),a prostate cancer

survivor and New York Yankees bench coach

Don Zimmer in Joe Torre’s office before a

Prostate Cancer Foundation CaP CURE

Home Run Challenge game.

Stewart Resnick and his wife, Lynda, a

PCF board member, have long been major

supporters of medical research and other

charities.They joined “Magicians of the

Century” Siegfried and Roy at a 2002 e vent

that raised several million dollars for PCF-

funded research.

Funding Research

15

In 2001, Novartis gained FDA

approval for Zometa for the treat-

ment of prostate cancer and other

solid tumors in bone.

Atrasentan In the early 1990s, a

drug called Atrasentan (formerly

designated ABT-627) was being

developed by Abbott Laboratories,

one of the largest pharmaceutical

companies in the world, to treat

cardiovascular disease. The drug

blocks the activity of a molecule

called endothelin that closes blood

vessels.A team of scientists at The

Johns Hopkins University discov-

ered that endothelin also caused

prostate cancer cells to grow. They

applied to the PCF for funds to test

Atrasentan.PCF-funded research

demonstrated that Atrasentan

slowed prostate cancer growth in

test tubes and in animal models.

Based on these results, Abbott

Laboratories has committed

hundreds of millions of dollars

The PCF:

We cut red tape.

We get results.

We provide hope.

Celestia Higano, a medical oncologist at the

University of Washington,describes results

from a recent clinical trial of a new drug for

advanced prostate cancer to PCF chairman

and founder Mike Milken at the 2001 PCF

Scientific Retreat at Lake Tahoe.

Gary Becker, Nobel laureate in economics,

spoke at the 2002 PCF Scientific Retreat.

Becker, considered one of the world’s leading

economists,has helped the PCF direct strate-

gies in research funding. Recognized for his

expertise in human capital,economics of the

family, and economic analysis of crime,

discrimination and population, Becker is a

prostate cancer survivor.

to the ongoing development of

Atrasentan to treat prostate cancer.

The drug is now in Phase III clinical

trials to determine wh et h er Atra s en t a n

can inhibit the growth of prostate

cancer cells in bone, relieve pain,

and improve quality of life for those

patients living with prostate cancer.

PCF participation was crucial to The

Johns Hopkins investigators because

funding for these types of “out-of-

the-box”studies is nearly impossible

to obtain. Without PCF funding

of this high-potential research,

Atrasentan may have never been

developed to treat prostate cancer.

Omnitarg Dr. David Agus, a medical

oncologist at Cedars-Sinai Health

Science Center in Los Angeles, was

formerly studying leukemia and

lymphoma at Memorial Sloan-

Kettering Cancer Center (MSKCC)

in New York.Scientists at MSKCC

rec ru i ted Dr. Agus to begin labora tory

16

studies to characterize new drug

candidates for prostate cancer. One

su ch dru g, produ ced by bi o tech-

n o l ogy company Genentech and

known as Omnitarg (formerly 2C4),

was studied by Dr. Agus and was

determined to be a potential treat-

ment for human prostate cancer.

Upon relocation to the Warschaw

Prostate Cancer Center at Cedars-

Sinai, a member of the PCF Therapy

Consortium,Dr. Agus was funded

to furt h er devel op Omnitarg. Arm ed

with these preclinical results in

prostate cancer, the PCF persuaded

G en en tech , a bi o tech n o l ogy com p a ny,

to conduct further development of

this drug candidate with pro s t a te

c a n cer as the lead indicati on .

This represents great progress

because most drugs are initial ly

tested in other cancers because of

the special challenges in evaluating

ef f i c acy in pro s t a te cancer. The

devel opm en t of Omnitarg is a

model case for the positive influence

of the PCF on pharmaceutical

companies to invest in prostate

cancer drug development.

PSMA Monoclonal Antibodies

Frequently, drugs developed by

PCF-funded investigators produce

treatments for many types of cancer.

PCF-funded research conducted

by Dr. Neil Bander at Cornell

University Medical School in New

York focuses on the use of a mono-

clonal antibody against Prostate-

Specific Membrane Antigen

(PSMA), a molecule found on

the surface of prostate cancer cells.

Monoclonal antibodies are proteins

engineered in the laboratory to bind

specifically and potently to a single

molecule. Intravenous injections

of monoclonal antibodies against

PSMA have been demonstrated to

concentrate at sites of prostate

cancer. This shows that they can

be used to deliver lethal doses of

Drugs developed by PCF-funded

investigators produce treatments

for all types of cancer.

Dr. Jonathan Simons, a medical oncologist

and Cancer Center director at Emory

University, is a PCF-funded physician/

sci en ti s t . Dr. Simons has made sign i f i c a n t

contributions in the area of prostate

cancer vaccines.

Intel chairman and PCF board memb er

Andrew Grove has helped accelerate the

pa ce of m edical re se a rch by sharing bu s i n e s s

principles that have led to success in the

high-tech industry. Dr. Grove is also a

prostate cancer survivor.

Funding Research

17

The PCF has significantly acceler-

ated the pace of discovery and

development of the most promising

prostate cancer treatments.

In 2001,the PCF sponsored a run/walk to

raise prostate cancer awareness. More than

5,000 men, women,and children assembled

at the Los Angeles Staples Center for the

Champions Challenge for a Cure.

Christopher Logothetis,M.D., chairman

of genitourinary medical oncology at the

University of Texas M. D. Anderson Cancer

Center, is at the forefront of clinical research

on prostate cancer. Dr. Logothetis was a

founding member of the Prostate Cancer

Foundation Therapy Consortium. At the

2002 PCF Scientific Retreat in Washington,

D.C.,he presented the results of his research

on specific gene-therapy approaches to

prostate cancer.

radiation or toxins directly to

prostate cancer, eradicating or

reducing the tumor.

Subsequent work showed that this

approach had even greater potential.

PSMA molecules, which had been

thought to exist only in prostate

cancer cells, were discovered on the

surface of cells lining new blood

vessels that feed many tumors in

addition to prostate cancer. This

suggested a potentially broad thera-

peutic activity of PSMA monoclonal

antibodies for breast, lung, and

colon cancers, in addition to

prostate cancer.

Realizing the potential of this new

treatment, biotechnology company

Millennium Pharmaceuticals is

currently funding the clinical devel-

opment of this PSMA monoclonal

a n ti body not on ly for pro s t a te cancer,

but potentially for other cancers as

well . At least two other ph a rm aceuti c a l

companies, Progenics and Medarex,

are developing their own PSMA

monoclonal antibodies specifically

for the treatment of prostate cancer.

These novel therapies illustrate

the progress being made. The hard

work of PCF-supported researchers

over the past 10 years is producing

therapies that are entering the

clinical-trial stage at an increased

rate. This provides hope for men

already living with prostate cancer,

as well as the approx i m a tely 220,000

men who will be diagnosed with

prostate cancer in 2003.

18

Increased Government Fu n d i n g

The Prostate Cancer Foundation

has been a strong and successful

advoc a te for incre a s ed govern m en t

funding for pro s t a te cancer

research. Since 1993, the PCF has

raised awareness that has helped

to i n c rease annual govern m ent

funding earmarked for prostate

cancer from $25 million to more

than $500 million. The increased

funding of prostate cancer research,

and cancer research in general,

has resulted in a major increase in

treatment programs.

National Cancer Institute

The PCF encouraged the National

Cancer Institute to expand its

Specialized Program of Research

Excellence program that helps to

accelerate the pace of development

of some of the most promising

prostate cancer drugs.

Since 1993, the PCF has raised

awareness that has helped to

increase annual government

funding earmarked for prostate

cancer from $25 million to

more than $500 million —

a 20-fold increase.

Specialized Program of

Research Excellence

The Specialized Program of

Research Excellence (SPORE)

encourages translational science

that spans the gap between basic

research and clinical applications.

The first two prostate cancer

SPOREs were funded in 1992

and increased to three in 1995.

Today, there are 11 prostate cancer

SPOREs with a total annual budget

of approximately $27 million.

The Department of

Defense Prostate Cancer

Research Program

In 1996, the PCF worked closely

with the National Prostate Cancer

Coalition and successfully urged

Congress to provide Department

of Defense funds specifically for

prostate cancer research under a

new mandate, the Prostate Cancer

International financier Thomas H. Lee

(left) attended the PCF Shadow Creek

Invitational along with Jerry West (center),

one of the 50 greatest players in NBA

history, and Dr. Howard Scher, a PCF-

funded investigator at Memorial Sloan-

Kettering Cancer Center in New York,an

internationally recognized investigator in

the field of genitourinary cancers.

The PCF supports physician/scientists at the

forefront of translational research.These

scientists advance drugs from the laboratory

bench to the patient ’s bedside. Translational

research scientists are one of the most impor-

tant catalysts for the development of new

therapies for advanced prostate cancer.

PCF boa rd mem ber David Ko ch and his wi fe ,

Ju l i a ,h ave long be en gen erous su ppo rters of

medical research and other charities.This

year, the PCF launched the D avid H. Koch

Awards.Mr. Koch’s extraordinary generosity

enabled the PCF to provide more than

$3 million to fund major research programs.

Funding Research

19

The Donald J. Trump Pro/Am Tennis

Invitational at the Mar-a-Lago Club in

Palm Be a ch has ra i sed more than $5 mill i o n

for prostate cancer research since the

program began in 1998.

Safeway joined the PCF in the fight against

prostate cancer with two longbed trucks that

travel throughout Northern and Southern

California. As part of a fund-raising effort

each year during the month of June,Safeway

and Vons customers made donations to the

PCF’s cancer-fighting efforts at chec kout

cou n ters .S a feway em pl oyees also pa rti ci pa ted

in a corporate donation drive.

Research Program (PCRP).

The PCRP’s mission promotes

innovative, multi-institutional,

multidisciplinary research aimed

at eradicating prostate cancer.

To date,the PCRP has provided

$395 million and has funded 797

peer-reviewed projects in response

to congressional appropriations.

The PCRP has become the secon d

l a r gest funder of prostate cancer

research in the United States.

This increase in federal support

has created a large and stable source

of funding needed to continue the

development of new drugs discov-

ered by PCF-funded research and

has attracted a critical mass of

scientists contributing to the

prostate cancer field.

As a result of the Prostate Cancer

Foundation’s advocacy, California

now requires that health insur-

ance companies and Medi-Cal

pay for routine treatment costs

incurred by cancer patients in

clinical trials.

20

William Clapp

Diagnosed with prostate

cancer at age 63.

When he changed doctors at age

63, William Clapp received his first

prostate specific antigen (PSA) test.

The results showed that he probably

had metastatic prostate cancer.

This simple blood test detects

the amount of prostate specific

antigens in the blood. The higher

the reading, the greater the likeli-

hood of prostate cancer.

Medical authorities recommend

that all men have annual PSA tests

beginning at age 50 (or age 40 for

African American men or those

with a family history of prostate

cancer since they are at higher risk).

Nonetheless, Mr. Clapp’s prior

physician had neglected to conduct

a PSA test.

Mr. Clapp’s own test results

prompted him to research the

disease thoroughly. “The more I

• Black men have the highest

incidence of prostate cancer in

the world.

• Compared to Caucasian men, they

are 1.5 times more likely to get

prostate cancer and 2.3 times more

likely to die from prostate cancer.

• Prostate cancer has the strongest

familial link of all major cancers.

learned,” he says, “the more afraid

I was of dying.” Mr. Clapp elected

to be treated by Dr. Philip Kantoff,

a Pro s t a te Ca n cer Fo u n d a ti on-

supported oncologist who heads

the Lank Center for Genitourinary

Oncology of the Dana-Farber

Ca n cer In s ti tute at Ha rva rd Med i c a l

School. Mr. Clapp participated in

a PCF-funded study that uses

chemotherapy before surgery.

Men such as William Clapp, with

very high PSA levels, are typically

poor candidates for surgery because

their disease often has spread to

other organs. “They receive hor-

mones plus radiation, and then you

just cross your fingers,” Dr. Kantoff

says. Because Mr. Clapp’s prostate

cancer appeared to be confined,

surgery was a possibility, especially

with the use of chemotherapy

before surgery.

Although the chemotherapy made

the difference between success and

failure, Dr. Kantoff says, “The story

here is the whole approach of

trying drugs preoperatively, which

is very labor- i n ten s ive and ex pen s ive

and would not have been possible

without the PCF’s vision and

funding.” Without it,Mr. Clapp

might have been written off as a

h opeless case. In s te ad , he has don e

extraordinarily well.

Mr. Clapp continued to work

during chemotherapy and missed

only a month of work after surgery.

Then, in May 2002,at age 65,he

retired. Now he spends his days

working out at a YMCA, taking

culinary arts classes, and playing

with his young grandsons. His PSA

has remained at zero for the past

two years. And he can look forward

once again.

His whole perspective on life has

changed.“I’m more calm now,

because there are more important

things in life.I want to live longer

than my grandfather, who died at

93.I think I can do it. I feel like I’m

born again.”

Family histories and genes may hold the

key to solving part of the prostate cancer

puzzle.The PCF Gene and Family Studies

Consortium created the largest repository of

genetic samples from families with multiple

individuals affected by prostate cancer. The

consortium partnered with academic experts

to discover cancer-related genes and targets

that can lead to new medications.

Patient Profile

“The moreI learned, the more afraid

I was of dying.”

22

The Prostate Cancer Foundation

has created and supported a series

of networks and consortia among

academic research scientists,

bi o tech n o l ogy and ph a rm aceuti c a l

com p a n i e s , govern m ent re s e a rch ers ,

and grassroots organizations

to maximize collaboration and

idea exchange. All PCF-funded

researchers are required to share

their findings with colleagues

around the globe and participate

actively with other research leaders.

Therapy Consortium

The PCF has assembled a team of

medical oncologists at eight leading

U.S. cancer centers that specialize

in prostate cancer research. The

m em bers of this Th era py Con s ortiu m

meet regularly to address major

i s sues that impede progress in cl i n i c a l

development of new treatments.

The Prostate Cancer Foundation

Research Therapy Consortium

in 2002:

• M. D. Anderson Cancer Center

• The Johns Hopkins University

• University of California,

San Francisco

• Memorial Sloan-Kettering

Cancer Center

• Cedars-Sinai Prostate Cancer Center

• University of Wisconsin

• University of Michigan

• Dana-Farber Cancer Institute,

Harvard Medical School

Members test each other’s ideas;

co ll a bora te in de s i gn i n g, con du cti n g,

and evaluating clinical trials, many

of which were funded by the PCF;

and develop new drugs and treat-

ments. Major contributions and

activities of the group include:

Collaboration

The PCF has assembled a

team of medical oncologists

at eight leading U.S. cancer

centers that specialize in

prostate cancer research.

A routine physical in 1997 brought the news

to professional golfer Jim Colbert that he had

prostate cancer. Now he’s joining golf legend

and fellow prostate cancer survivor Arnold

Palmer in a partnership between the

Champions Tour and the PCF to rais e

funds for prostate cancer research.

Donald S. Coffey, Ph.D. (left), considered the

“f a t h er of pro s t a te cancer re se a rch ,” is profe s so r

of urology, oncology and pharmacology and

molecular sciences at The Johns Hopkins

Un ivers i ty. Dr. Cof fey disc u s sed the PCF’s 10

years of progress with PCF medical director,

Stuart Holden,M.D. (right),and Leslie D.

Michelson,PCF vice chairman and C E O,

at the PCF Ninth annual Sci en tific Retre a t .

23

• Establishing taxane-based

ch em o t h era py as a tre a tm ent opti on

for advanced prostate cancer;

• Acting as a planning group to initi a te

new academic and industrial trials

for prostate cancer treatments;

• Screening new drugs for inclusion

in trials;

• Participating in clinical-trial

standardization programs; and

• Working together to select a clinical

research informatics system to link

the participating centers.

Scientific Retreat

The Prostate Cancer Foundation

Scientific Retreat has become one

of the most prominent annual

m edical events in the nati on ,d rawing

hundreds of pioneering scientists

and physicians, government leaders,

prostate cancer advocates,and

bi o tech and ph a rm aceutical com p a ny

executives. For three intensive days,

these leaders address scientific

advances, present ongoing research,

deb a te topical issues rel a ted to pro s t a te

cancer, and examine better ways to

fund research and produce results.

The 2002 Prostate Cancer

Foundation Scientific Retreat was

h eld in Wa s h i n g ton , D. C . to high l i gh t

the import a n ce of the govern m en t’s

role in our efforts. Dr. Andrew von

Eschenbach, newly appointed by

President Bush as director of the

Na ti onal Ca n cer In s ti tute and a

pro s t a te cancer su rvivor, s po ke

eloquently of the Prostate Cancer

Fo u n d a ti on’s ef fectiveness in “get ti n g

done the things that need to be don e .”

The PCF selects and provides

funding for high-impact

projects capable of producing

cutting-edge results by some

of the world’s most forward-

thinking scientists.

Businessman Carl Lindner (left), owner

of the Cincinnati Reds and Honorary PCF

board member, has been an avid and

generous supporter of the Prostate Cancer

Fou n d a tion CaP CURE Home Run Chall en ge .

Several hundred thousand people from more

than 600 cancer groups across America met

on the Washington Mall in 1998 for THE

MARCH: Coming Together to Cure Cancer.

THE MARCH helped raise awareness of

cancer issues on Capitol Hill and preceded

a major increase in government funding of

prostate cancer research.

24

The Prostate Cancer

Foundation in Israel

The Prostate Cancer Foundation

began funding research programs

in Israel three years ago. Since

inception, nearly $4.7 million has

been provided to 59 programs.

The PCF has achieved many of the

objectives in Israel that have been

benchmarks of PCF activities in

the U.S. Specifically, the PCF has

recruited the best and brightest to

the field, initiated venture programs,

and fac i l i t a ted significant net work i n g

among scientists from many

Israeli institutions. In addition,

the PCF initiated a Centers of

Excellence program that requires

multiple centers to join in a single

proposal with significant impact on

the science of prostate cancer. In

2002, the PCF funded a Centers of

Excellence award that joined the

Technion Institute,the Weizmann

Institute,and Hadassah University

Hospital. This multidisciplinary

program has the po ten tial to gen era te

new drug t a r gets for the tre a tm ent of

rec u rren t prostate cancer.

This program is the PCF’s first step

in linking scientific leaders from

around the world in an intensified

effort to find better treatments and

a cure for prostate cancer.

Partnering with Industry

Moving a treatment from lab to

market can take as long as 12 years.

For the Prostate Cancer Foundation,

that is simply too slow. That is

why the PCF works closely with

biotechnology and pharmaceutical

companies to get re s e a rch innova ti on s

to patients faster.

PCF funding has all owed inve s ti ga tors

to accelerate the pace of develop-

m ent of the most promising pro s t a te

cancer treatments by:

• Funding the underlying science that

led to the treatment being studied;

• Funding early clinical trials; and

• Encouraging and assisting

the company.

Cincinnati Reds outfielder Ken Griffey Jr.

is a Prostate Cancer Foundation CaP CURE

Home Run Challenge featured star represen-

tative. With such awesome power supporting

the 2003 Home Run Chall en ge , it was anot h er

groundbreaking year for the PCF in its

mission to find better treatments and a cure

for prostate cancer.

Steve Burd (left), Safeway president

and CEO, introduces Prostate Cancer

Foundation chairman Mike Milken at

Safeway’s kickoff to its month-long

campaign to raise money for prostate

cancer research.

Collaboration

PCF chairman Mike Milken (second from

right) stands with some of the PCF’s biggest

Home Run Challenge supporters. From left:

Former A’s and Twins catcher and founding

Home Run Challenge co-chair Terry

Stei n ba ch and Ba l ti m o re Ori oles minori ty

owners Bill Beatson Jr. and Steve Geppi.

The Prostate Cancer Foundation

and the investigators it funds

work closely with many pharma-

ceutical and biotech companies

including: Abbott Laboratories,

Bayer, Cell Genesys, Genentech,

G l a x o S m i t h Kline, Medarex, Merck,

Millennium Pharmaceuticals,

Novartis, and Pfizer.

25

Since 1996, the PCF has part-

nered with Major League Baseball

and the Major League Baseball

Players Association to raise more

than $18 million for prostate

cancer research.

Lowell Milken (left) with PCF medical

director Stuart Holden,M.D. (far right)

at the 2001 PCF Scientific Retreat held at

Lake Tahoe, Nevada. Lowell Milken,

co - fou n d er of the Mi l ken Fa m i ly Fou n d a ti o n ,

has been one of the top supporters of the

PCF since its inception in 1993.

The Prostate Cancer Foundation

conducts many programs aimed at

raising not only research f u n d i n g

but also public aw a reness of the

significance of prostate cancer.

The Prostate Cancer

Foundation CaP CURE

Home Run Challenge

Since 1996, the PCF has partnered

with Major League Baseball and

the Major League Baseball Players

As s oc i a ti on to raise more than

$18 mill i on for pro s t a te cancer

re s e a rch . E ach Ju n e , fans pled ge

anywhere from 25 cents to $10,000

for every home run hit in 60 sel ected

games the week before Father’s Day.

All 30 Major League Baseball teams

provide support for the Home

Run Challenge in many ways. Clubs

host pregame ceremonies, run pub-

lic s ervi ce announcem en t s , don a te

ti cket s , place blue ribbons on

the field,and support the player

repre s en t a tive s . In ad d i ti on ,a ll Ma j or

League managers, such as Joe Torre

of the New York Yankees and Dusty

Baker of the Chicago Cubs, both

prostate cancer survivors, also par-

ti c i p a te . Own ers , exec utive s , coach e s ,

umpires, trainers, groundskeepers,

and front office staff are behind

the cause by hosting sp ecial events

en dorsing and prom o ting the Hom e

Run Challenge.

Safeway and the Prostate

Cancer Foundation

Safeway, one of the largest food

ret a i l ers in North Am eri c a ,p a rtn ered

with the PCF for a third year in a

row to raise money and awareness.

Steve Burd, Safeway’s president and

ch i ef exec utive of f i cer, l ed a com p a ny -

wide campaign that included

Raising Money

and Awareness

26

point-of-purchase promotions at

more than 15,000 checkout stands

in all 1,600 Sa few ay stores in the U. S .

Employees also participated in

i n ternal fund-raising drives to boo s t

proceeds. In 2003, the campaign

raised more than $2.5 million for

prostate cancer research.

Champions Tour for the Cure

Led by golf legends and prostate

cancer survivors Arnold Palmer, Jim

Co l bert , Bobby Wa l zel , and Ray Floyd ,

this program focuses on fans of the

Champions Tour. Supporters pledge

$1 or more for each birdie made by

their favorite player(s) during the

s e a s on . Every bi rdie made bet ween the

MasterCard Championship in late

January through the season-ending

Champions Tour Championship

at Gaillardia in October supports

prostate cancer research.

Arnie’s Army

Named for honorary chair Arnold

Palmer, this program involves

p a rti c i p a ting go l f co u rses spon s ori n g

one-day, closest-to-the-pin contests

on a pre s el ected par-3 hole. Ba n n ers ,

tee markers, pin flags, and other

collateral materials carry the

program logo and all golfers are

encouraged to join Arnie’s Army

to raise funds and generate public

awareness of prostate cancer.

In 2002, the Prostate Cancer

Foundation began the program

in the North Florida section of the

PGA. This year, Arnie’s Army moves

across the nation with the goal of

enlisting hundreds of golf courses

and thousands of golfers.

Raising Money

and Awareness

Boxing champion and Olympic gold

medalist Sugar Ray Leonard joined fashion

designer Pamela Dennis and other celebrities

at the PCF Shadow Creek Invitational golf

tournament fund-raising event.

Ha ll of Fame hockey legend Wayne Gret z k y

participated at the PCF Champions

Challenge for a Cure Run/Walk at the

Staples Center in Los Angeles.The annual

walk and interactive sports festival is a

family event that increases awareness of the

effects of prostate cancer on men and their

families,and raises money to increase cancer

research funding.

Talk show host Larry King joined Whoopi

Goldberg,mistress of ceremonies at the 1998

PCF New York Dinner. Larry has often

featured PCF chairman and founder Mike

Milken on his television show to discuss

prostate cancer research.

The Prostate Cancer Foundation

has supported research on the

effects of nutrition on prostate

cancer and other serious diseases.

27

Every other year, the PCF hosts a fund-

raising event at the Waldorf-Astoria Hotel

in New York to raise money for p rostate

cancer research. Past honorees Steve and

Elaine Wynn (center) receive the PCF eagle

statuette presented by Honorary PCFboard

member Robert Wagner and his wi fe ,

Ji ll St . Joh n ,( l eft) and PCF ch a i rm a n and

founder Mike Milken (right).

Named for honorary chair Arnold Palmer,

a prostate cancer survivor, the Arnie’s Army

program involves participating golf courses

s po n so ring one-day, cl o se s t - to-the-pin co n te s t s

on a preselected par-3 hole. Golfers are

encouraged to join Arnie’s Army to raise

funds and generate public awareness of

prostate cancer.

Producer/songwriter David Foster (right), a

1 4 - time Gra m my Awa rd wi n n er, and ren own ed

Australian golf legend Greg Norman provide

some en tert a i n m ent at the PCF Sh a d ow Cre e k

Invitational golf tournament to raise money

for prostate cancer research.

Nutrition

Scientists now know that prostate

cancer, like all cancers,is the result

of damage to certain genes that

regulate the growth and death of

cells. This damage is caused by a

complex, but incompletely under-

s tood ,i n teracti on bet ween hered i ty

and environment.

Di f ferent types of s c i en tific evi den ce

collectively suggest that diet and

lifestyle may account for or con-

tribute to a significant portion of

cancers, including prostate cancer.

For example,the incidence of

prostate cancer in Asian men, whose

diets have relatively small amounts

of fat and large amounts of soy

protein, is much less than that in

American men. Yet, when Japanese

men migrate to the United States

and adopt American eating habits,

their rate of prostate cancer rises to

American levels within a generation.

In addition, basic science research

on animals and cells, and clinical

trials evaluating specific nutrition

and lifestyle changes in men,show

the importance of nutrition in

preventing cancer.

From its earliest days, the Prostate

Cancer Foundation has supported

research on the effects of nutrition

on prostate cancer and other serious

diseases. And we have published

the results of those studies to pro-

vide practical guidance for patients.

The PCF has invested more than

$4 mill i on in nutri ti onal re s e a rch at

13 leading re s e a rch cen ters inclu d i n g

Harvard University, The Johns

Hopkins Un ivers i ty, M I T, Mem ori a l

Sloan-Kettering Cancer Center,

Rockefeller University, and the

U C LA Cen ter for Human Nutri ti on .

Researchers have investigated the

value of a low-fat, high-fiber diet

rich in fruits, vegetables, and grains,

as well as foods believed to contain

beneficial properties, including s oy

pro tei n , coo ked tom a to produ ct s ,

and cruciferous vegetables such

as broccoli.

The PCF has invested more than

$4 million in nutritional research

at 13 leading research centers.

28

When former New York city schools official

Harold Kobliner, Ph.D. was diagnosed with

prostate cancer, he and his family searched

for answers.The PCF’s nutrition project

presented an alternative therapy supported

by ongoing scientific research.

Nutrition and Prostate Cancer: A

Monograph from the PCF Nutrition

Project gives prostate cancer patients nutri-

tional approaches to fighting the disease.

Although the evidence provides few

absolute truths, studies show that:

• Men who eat more cooked tomato

products had fewer cases of prostate

cancer. Lycopene, a powerful antiox-

idant, is released and becomes more

bioavailable when tomatoes are

heated. It may inhibit processes in

the body that lead to cancer.

• A low-fat,high-fiber diet rich in

fruits, vegetables, soy, and grains

may halt, or even reverse,the

growth of prostate cancer.

• Men who consume large quantities

of red meat and dairy products may

increase their risk of prostate cancer.

• Being overweight increases the

risk of virtually every cancer. An

American Cancer Society study

showed that overweight men were

52% more likely to die from cancer

than men of normal weight.

To help men understand these and

other findings and adopt healthier

lifestyles,the Prostate Cancer

Foundation has published two

cookbooks, The Taste for Living

Cookbook, and The Taste for Living

WORLD Cookbook. Both contain

great-tasting, thoroughly tested,

easy-to-prepare recipes. We have

also published the fourth edition

of the monograph Nutrition and

Pro s t a te Cancer, wh i ch de s c ri bes the

current state of nutrition research.

Both cookbooks and the mono-

graph are available on our web site:

www.prostatecancerfoundation.org.

Raising Money

and Awareness

Men who eat more cooked tomato products

had fewer cases of prostate cancer. Lycopene,

a powerful antioxidant,is released and

becomes more bioavailable when tomatoes

are heated. It may inhibit processes in the

body that lead to cancer.

29

We didn’t get to these people in time.

We can and must do more. The need remains great.

Your help has never been more important.

Timothy Leary 1920-1996

Telly Savales 1924-1994Steve Ross 1927-1993

Francois Mitterand 1916-1996

Linus Pauling, Ph.D. 1901-1994Jay Chiat 1934-2002

Bill Bixby 1934-1993

Frank Zappa 1941-1993

30

Professor Gerald Haslam

Diagnosed with prostate

cancer at age 60.

When author and professor Gerald

Haslam retired after 30 years at

Ca l i fornia State Un ivers i ty, l i fe wasn’t

what he expected. Just months after

undergoing prostate surgery and

radiation treatment, the news from

one of his follow-up visits was

devastating: his PSA level was on

the rise. His physician feared that

his cancer had retu rn ed and referred

him to the University of California,

San Francisco (UCSF), a leading

cancer center and one of eight

members of the Prostate Cancer

Foundation Therapy Consortium.

Dr. Eric Small, an oncologist,

enrolled Mr. Haslam in a PCF-

funded clinical trial of an innovative

form of immunotherapy that stimu-

lates the body’s immune system

to eradicate prostate cancer cells.

Immunotherapy is similar in theory

to receiving a vaccine or flu shot.

Compared to other treatments for

prostate cancer, immunotherapy has

proven to be relatively nontoxic.

“I’d always planned to retire at 60,”

Professor Haslam says,“just not

under these circumstances. I was

a lw ays an athlete and sti ll con s i dered

myself young and alive.”

“The best patient care always comes

from integrating the most innova-

tive and novel therapeutics with a

vigorous research program,” says Dr.

Small. “Without the PCF’s financial

support of UCSF’s immunotherapy

research, Mr. Haslam’s treatment

options would have been limited.

Our participation in the Prostate

Cancer Foundation Therapy

Consortium has helped transform

us into a top-tier cancer center.

We strengthened our research

infrastructure to complement the

expertise we already had.”

• One in six men will get prostate

cancer in their lifetimes.

• Every 2 1/2 minutes a man is

diagnosed with prostate cancer.

• Ever 18 minutes, a man dies

from prostate cancer in the

United States.

Dr. Small’s colleague,urologist

Peter Carroll,agrees. “The PCF

gave us not only the impetus, but

the guidance to become better. As

a result, we have been able to help

many more patients with high-risk

prostate cancer.”

Today, Mr. Haslam’s PSA is down

to an acceptable level. He continues

his fight against prostate cancer and

expects to enter another clinical trial

involving the hereditary factors of

the disease. Because his family has

a history of prostate cancer, he and

his three sons are also participating

in a PCF-funded study of familial

predisposition for prostate cancer.

“Wh en I do die, my death wi ll have

been of value in the long-term

struggle. And if something I experi-

ence helps my sons down the road,

that’s a wonderful gift. Hope in any

form is priceless,” says Mr. Haslam.

Gerald Haslam continues his fight against

prostate cancer and expects to enter another

clinical trial involving the hereditary factors

of the disease. Because his family has a his-

tory of prostate cancer, he and his three sons

are also participating in a PCF-funded study

of familial predisposition for prostate cancer.

Patient Profile

“ I ’d alw ays planned to reti re at 60, just not under

these circ u m s t a n ce s .”

32

Research Awards

2002 David H. Koch Aw a r d s

This year the Prostate Cancer

Foundation launched the David

H. Koch Awards. Mr. Koch’s

extraordinary generosity enabled

the PCF to provide more than

$3 million to fund major research

programs at:

• The Johns Hopkins University

• M. D. Anderson Cancer Center

• Memorial Sloan-Kettering

Cancer Center

Albert Einstein College of Medicine

$75,000

Nicole B. Schreiber-Agus,Ph.D.

Assaf Harofe Medical Center (Israel)

$150,000

Amnon Zisman,M.D.

Bar-Ilan University (Israel)

$225,000

Shlomo Grossman,Ph.D.

Uri Nir, Ph.D.

Baylor University

$3,200,000

Jacques Banchereau,Ph.D.

Baylor College of Medicine

Norman M. Greenberg, Ph.D.

Dov Kadmon,M.D.

Paula Kaplan-Lefko, Ph.D.

Michael Kattan,Ph.D.

Dolores J. Lamb, Ph.D.

Bert W. O’Malley, M.D.

David R. Rowley, Ph.D.

Peter T. Scardino, M.D.

Timothy C. Thompson,Ph.D.

Ming-Jer Tsai,Ph.D.

Nancy L. Weigel,Ph.D.

Ben-Gurion University

of the Negev (Israel)

$375,000

Ron N. Apte,Ph.D.

Joseph Levy, Ph.D.

Angel Porgador, Ph.D.

Shraga Segal,Ph.D.

Brandeis University

$250,000

Lizbeth Hedstrom,Ph.D.

Gregory A. Petsko, Ph.D.

Burnham Institute

$1,686,000

Wadih Arap, M.D.,Ph.D.

Nuria E. Assa-Munt,Ph.D.

Kathryn R.Ely, Ph.D.

John C. Reed,M.D.,Ph.D.

Erkki I Ruoslahti,M.D.,Ph.D.

California Institute of Technology

$450,000

Raymond J. Deshaies,Ph.D.

Huatao Guo, Ph.D.

Alexander J. Varshavsky, Ph.D.

California Pacific Medical Center

$100,000

Robert J. Debs,M.D.

Cancer Institute of New Jersey

$75,000

Robert S. DiPaola,M.D.

Cantonal Hospital St.Gall

(Switzerland)

$75,000

Marcus Groettrup, Ph.D.

Case Western Reserve University

$275,000

Sanford Markowitz,M.D.,Ph.D.

Bingcheng Wang, Ph.D.

Cedars-Sinai Medical Center

$1,995,000

David B. Agus,M.D.

H.Phillip Koeffler, M.D.

Isett Laux,Ph.D.

Cleveland Clinic Foundation

$150,000

Katerina Gurova,Ph.D.

Edward Plow, Ph.D.

Cold Spring Harbor Laboratory

$100,000

Robert Lucito, Ph.D.

Columbia University

$2,129,500

Allen Pavilion Presbyterian Hospital

Carl A. Olsson,M.D.

Atchley Pavilion

Ralph Buttyan,Ph.D.

College of Physicians and Surgeons

Paul B. Fisher, Ph.D.

Aaron E. Katz,M.D.

Nickolas Papadopoulos,Ph.D.

Columbia Presbyterian Medical Center

Daniel Petrylak,M.D.

33

Cornell University

$4,100,000

Beatrice S. Knudsen,M.D.,Ph.D

David M. Nanus,M.D.

New York Presbyterian Hospital

Neil H. Bander, M.D.

Dartmouth-Hitchcock

Medical Center

$75,000

Marc S.Ernstoff,M.D.

Duke University

$925,000

Eli Gilboa,Ph.D.

Michael C.Pirrung, Ph.D.

David T. Price,M.D.

Johannes W. Vieweg, M.D.

Eastern Virginia Medical School

$175,000

George L. Wright Jr.,Ph.D.

Emory University

$250,000

Wayne Harris,M.D.

John A. Petros,M.D.

Erasmus University (Netherlands)

$250,000

Jan Trapman,Ph.D.

Gert J. van Steenbrugge,Ph.D.

Fred C. Hutchinson Cancer

Research Center

$2,605,000

Peter S. Nelson,M.D.

Elaine A.Ostrander, Ph.D.

Janet L.Stanford,Ph.D.

Georgetown University

$1,000,000

Lombardi Cancer Center

Edward P. Gelmann,M.D.

Robert L. Martuza,M.D.

Renxiao Wang, Ph.D.

Shaomeng Wang, Ph.D.

Hadassah University (Israel)

$425,000

Rachel Bar-Shavit,Ph.D.

Eithan Galun,M.D.,Ph.D.

Amnon Peled,Ph.D.

Eli Pikarsky, M.D.,Ph.D.

Israel Vlodavsky, Ph.D.

Harvard University

$10,625,000

Beth Israel Deaconess Medical Center

Lewis C. Cantley, Ph.D.

John V. Fragioni,M.D.,Ph.D.

Sandra M.Gaston,Ph.D.

Towia A.Libermann,Ph.D.

Massimo Loda,M.D.

Jan E.Schnitzer, M.D.

Brigham and Women’s Hospital

Anthony V. D’Amico, M.D.,Ph.D.

Phillip Febbo, M.D.

James W. Fett,Ph.D.

Joshua LaBaer, M.D.,Ph.D.

Kevin R. Loughlin,M.D.

Karen A. Olson,Ph.D.

Jeffrey L. Sklar, M.D.,Ph.D.

Children’s Hospital

Judah Folkman,M.D.

Michael Klagsburn,Ph.D.

Calvin J. Kuo, M.D.

Marsha A. Moses,Ph.D.

Richard C. Mulligan,Ph.D.

Bruce R. Zetter, Ph.D.

Dana-Farber Cancer Institute

Ranaan Berger, M.D.,Ph.D.

Myles A. Brown,M.D.

Harvey Cantor, M.D.

Diego Castrillon,M.D.,Ph.D

Lan Bo Chen,Ph.D.

Glenn Dranoff,M.D.

Daniel J. George,M.D.

William C. Hahn,M.D.,Ph.D.

Philip W. Kantoff,M.D.

David M.Livingston,M.D.

Massimo Loda,M.D.

Thomas Roberts,Ph.D.

William R. Sellers,M.D.

Sabina Signoretti,M.D.

Bruce M.Spiegelman,Ph.D.

Robert H. Vonderheide,M.D., D.Phil.

Harvard School of Public Health

June M. Chan,Sc.D.

Edward Giovannucci,M.D.

Laurie H.Glimcher, M.D.

Dimitrios Trichopoulos,M.D.

Massachusetts General Hospital

Joel Finkelstein,M.D.

Robert L. Martuza,M.D.

Matthew R. Smith,M.D.,Ph.D.

Ching-Hsuan Tung, Ph.D.

Anthony L. Zietman,M.D.

Hebrew University (Israel)

$800,000

Yinon Ben-Neriah,M.D.,Ph.D.

Howard Cedar, M.D.,Ph.D.

Eli Keshet,Ph.D.

Alexander Levitzki,Ph.D.

David Naor, Ph.D.

Indiana University

$200,000

Thomas A.Gardner, M.D.

George W. Sledge,M.D.

Institute for Systems Biology

$500,000

Leroy E. Hood,M.D.,Ph.D.

John Wayne Cancer Institute

$50,000

Frederick R. Singer, M.D.

Johns Hopkins University

$12,897,000

Philip A. Beachy, Ph.D.

G.Steven Bova,M.D.

Michael A. Carducci,M.D.

Angelo DeMarzo, M.D.,Ph.D.

Samuel R. Denmeade,M.D.

Mario Eisenberger, M.D.

John T. Isaacs,Ph.D.

William B. Isaacs,Ph.D.

Hyam I. Levitsky, M.D.

Joel B. Nelson,M.D.

William G. Nelson,M.D.,Ph.D.

Alan W. Partin,M.D.,Ph.D.

Ronald Rodriguez,M.D.,Ph.D.

Jonathan W. Simons,M.D.

Patrick C. Walsh,M.D.

34

Karolinska Institute (Sweden)

$75,000

Hans-Olov Adami,M.D.,Ph.D.

Klinikum de Justus-Liebig

Universitat Giessen (Germany)

$175,000

Trinad Chakraborty

La Jolla Institute for

Allergy and Immunology

$75,000

Stephen Schoenberger, Ph.D.

Long Island College Hospital

$15,000

Ivan Grunberger, M.D.

Loyola University Medical Center

$200,000

Eugene D. Kwon,M.D.

McGill University

$75,000

Nahum Sonenberg, Ph.D.

Massachusetts Institute

of Technology

$1,535,000

Sandra M.Gaston,Ph.D.

Richard O. Hynes,Ph.D.

Jun Liu,Ph.D.

Peter H. Seeberger, Ph.D.

Ganesh Venkataraman,Ph.D.

Whitehead Institute for

Biomedical Research

John M.Essigmann,Ph.D.

Eric S.Lander, Ph.D.

Richard C. Mulligan,Ph.D.

Mayo Clinic and Foundation

$500,000

Lorraine A.Fitzpatrick,M.D.

John C. Morris,M.D.

Donald J. Tindall,Ph.D.

Memorial Sloan-Kettering

Cancer Center

$14,060,000

David B. Agus,M.D.

William R. Fair, M.D., F.A.C.S.

George Farmer, Ph.D.

Leonard P. Freedman,Ph.D.

Zvi Fuks,M.D.

Polly Gregor, Ph.D.

Adriana Haimovitz-Friedman,Ph.D.

Warren D.W. Heston,Ph.D.

William Kevin Kelly, M.D.

Philip O. Livingston,M.D.

Paul A. Marks,M.D.

Michael R. McDevitt,Ph.D.

David Nanus,M.D.

Neal Rosen,M.D.,Ph.D.

Michael Sadelain,M.D.,Ph.D.

Peter T. Scardino, M.D.

David A.Scheinberg, M.D.,Ph.D.

Howard I.Scher, M.D

George Sgouros, Ph.D.

David Shaffer, M.D.,Ph.D.

Moshe Shike, M.D.

Susan F. Slovin,M.D.,Ph.D.

Peter Smith-Jones,Ph.D.

Jedd D. Wolchok,M.D.,Ph.D.

Menzies Centre for Population

Health Research (Australia)

$50,000

David A. Mackey, M.D.

Mount Sinai School of Medicine

$275,000

Michael J. Droller, M.D.

Irwin H.Gelman,Ph.D.

John A. Martignetti,M.D.,Ph.D.

New York Medical College

$150,000

Cancer Research Institute

Sophie Chen,Ph.D.

New York University

$430,000

Maarten C. Bosland, D.V.Sc.,Ph.D.

Herbert Lepor, M.D.

Ian J. Mohr, Ph.D.

Samir Taneja,M.D.

Skirball Institute of

Biomolecular Medicine

Ruben Abagyan,Ph.D.

Northwest Hospital

$475,000

Gerald P. Murphy, M.D., D.Sc.

Research Awards

35

Northwestern University

$200,000

Wade Bushman,M.D.,Ph.D.

Zhou Wang, Ph.D.

Ohio State University

$100,000

M. Guill Wientjes Ph.D.

Oregon Health Sciences University

$100,000

Ron G. Rosenfeld,M.D.

Preventive Medicine Research

Institute

$500,000

Dean Ornish,M.D.

Rabin Medical Center (Israel)

$50,000

Avishay Sella,M.D.

Rockefeller University

$500,000

Robert G. Roeder, Ph.D.

Strang Cancer Research Laboratory

Martin Lipkin,M.D.

Salk Institute for Biological Studies

$760,050

Ronald M. Evans,Ph.D.

San Diego Cancer Research

$75,000

R. Michael Williams,M.D.,Ph.D.

Scripps Research Institute

$975,000

Ruben A. Abagyan,Ph.D.

K.C. Nicolaou,Ph.D.

Prabhakar Tripuraneni,M.D.

Sheba Medical Center (Israel)

$150,000

Gideon Rechavi,M.D.,Ph.D.

Stanford University

$1,225,000

Gerald R. Crabtree,M.D.

David Feldman,M.D.

Calvin J. Kuo, M.D.

John E. McNeal,M.D.

Donna M. Peehl,Ph.D.

Thomas A.Stamey, M.D.

St.Louis University

$75,000

William S.M. Wold,Ph.D.

State University of New York

$112,500

Downstate Medical School

Jack Mydlo, M.D.

Stony Brook

Victor I. Romanov, Ph.D.

Technion, Israel Institute of

Technology (Israel)

$625,000

Ami Aronheim,Ph.D.

Aaron Ciechanover, M.D., D.Sc.

Fuad Fares, D.Sc.

Ehud Keinan,Ph.D.

Gera Neufeld,Ph.D.

Israel Vlodavsky, Ph.D.

Tel-Aviv University (Israel)

$400,000

Zvi Fishelson,Ph.D.

Sara Lavi,Ph.D.

Ada Rephaeli,Ph.D.

Ilan Tsarfaty, Ph.D.

Sourasky Medical Center

Ben-Zion Katz,Ph.D.

Avi Orr-Urtreger, M.D.,Ph.D.

Thomas Jefferson University

$125,000

Michael J. Mastrangelo, M.D.

Albert J. Wong, M.D.

Tulane University

$500,000

Andrew V. Schally, M.D.,Ph.D.

University Hospital,

Nijmegen (Netherlands)

$275,000

Marion J.G. Bussemakers,Ph.D.

University of Alabama, Birmingham

$100,000

David T. Curiel,M.D.

University of Arizona

$150,000

Leslie Gunatilaka,Ph.D., B.S.

Mark W. Kunkel,Ph.D.

University of Basel (Switzerland)

$75,000

Lukas Bubendorf,M.D.

University of Bern (Switzerland)

$100,000

George N. Thalmann,M.D.

University of California

$15,990,068

Lawrence Livermore

National Laboratory

Christine Hartmann Siantar, Ph.D.

University of California, Berkeley

James P. Allison,Ph.D.

Carolyn Bertozzi,Ph.D.

Arthur A. Hurwitz,Ph.D.

David H. Raulet,Ph.D., B.S.

Peter G.Schultz,Ph.D.

David E. Wemmer, Ph.D.

University of California, Davis

Shing-Jien Kung, Ph.D.

University of California, Los Angeles

Arie S. Belldegrun,M.D.

Michael F. Carey, Ph.D.

Rowan T. Chlebowski,M.D.,Ph.D.

Pinchas Cohen,M.D.

Jean B. deKernion,M.D.

Purnima Dubey, Ph.D.

Sanjiv S.Gambhir, M.D.,Ph.D.

David Heber, M.D.,Ph.D.

Harvey R. Herschman,Ph.D.

Jay R.Lieberman,M.D.

Carl W. Miller, Ph.D.

Ayyappan K. Rajasekaran,Ph.D.

Robert Reiter, M.D.

Peter Rosen,M.D.

Marc A. Seltzer, M.D.

Kathleen M. Sakamoto, M.D.

Charles L. Sawyers,M.D

Marc A. Seltzer, M.D.

Ke Shuai,Ph.D.

Peter Tontonoz,M.D.,Ph.D.

Owen N. Witte,M.D.

Hong Wu,M.D.,Ph.D.

36

University of California,San Diego

Dennis A. Carson,M.D.

Randolph D. Christen,M.D.

Lawrence S.B. Goldstein,Ph.D.

Michael G. Rosenfeld,Ph.D.

Helen P. Tighe,Ph.D.

Maurizio Zanetti,M.D.

University of California,San Francisco

Jeffrey Arbeit,M.D.

Allan Balmain,Ph.D.

Elizabeth Blackburn,Ph.D.

Peter R. Carroll,M.D.

June Chan,Sc.D.

Robert Fletterick,Ph.D.

Mark W. Frohlich,M.D.

Douglas Hanahan,Ph.D.

Ronald H. Jensen,Ph.D.

John Kurhanewicz,Ph.D.

James D. Marks,M.D.,Ph.D.

Dean Ornish,M.D.

Mack Roach,III,M.D.

Eric J. Small,M.D.

Thea Tlsty, Ph.D.

University of California,Santa Barbara

Dulal Panda,Ph.D.

University of Chicago

$425,000

Douglas K. Bishop, Ph.D.

Carrie W. Rinker-Schaeffer, Ph.D.

Mitchell H. Sokoloff,M.D.

Ben May Institute for Cancer Research

Shutsung Liao, Ph.D.

University of Colorado

$655,000

L. Michael Glode,M.D.

William E. Huffer, M.D.

Andrew S. Kraft,M.D.

Gary J. Miller, M.D., Ph.D.

University of Connecticut

$100,000

Pramod Srivastava,Ph.D.

University of Edinburgh (Scotland)

$75,000

Fouad K. Habib, Ph.D.

University of Helsinki (Finland)

$200,000

Institute of Biomedicine

Olli A. Janne,M.D.,Ph.D.

University of Illinois

$50,000

Nissum Hay, Ph.D.

University of Innsbruck (Austria)

$100,000

Zoran Culig, M.D.

University of Iowa

$75,000

George Weiner, M.D.

University of Kentucky

$100,000

Vivek M. Rangnekar, Ph.D.

University of Maryland

$100,000

Natasha Kyprianou,Ph.D.

University of Massachusetts

$325,000

Michael R. Green,M.D.,Ph.D.

Shuk-Mei Ho, Ph.D.

Mani Menon,M.D.

University of Michigan

$3,000,000

Arul M. Chinnaiyan,M.D.,Ph.D.

Mark Day, Ph.D.

Evan T. Keller, D.V.M.,Ph.D.

Donna Livant,Ph.D.

Kenneth J. Pienta,M.D.

Martin G. Sanda,M.D.

Shaomeng Wang, Ph.D.

University of Munich (Germany)

$100,000

Bernd Gansbacher, M.D.

University of Nebraska

$100,000

Ming-Fong Lin,Ph.D.

University of North Carolina,

Chapel Hill

$150,000

David Ornstein,M.D.

University of Pennsylvania

$400,000

Mark I. Greene, M.D.,Ph.D.

Research Awards

37

Wistar Institute

George C. Prendergast,Ph.D.

University of Pittsburgh

$2,275,000

Michael J. Becich,M.D.,Ph.D

Barbara A. Foster, Ph.D

John Gilbertson,M.D.

Susan L. Greenspan,M.D.

Candace S. Johnson,Ph.D.

Joel B. Nelson,M.D.

Donald L. Trump, M.D.

Janey Whalen,Ph.D.

University of Rochester

$400,000

Chawnshang Chang, Ph.D.

Edward Messing, M.D.

University of Southern California

$100,000

Donald G. Skinner, M.D.

University of Tampere (Finland)

$300,000

Tapio Visakorpi,M.D.,Ph.D.

University of Tennessee

$150,000

Jeffrey Gingrich,M.D.

University of Texas

$10,917,000

Health Science Center at San Antonio

Susan Padalecki,Ph.D.

The M.D. Anderson Cancer Center

Wadih Arap, M.D.,Ph.D.

Danai Daliani,M.D.

John DiGiovanni,Ph.D.

Isaiah J. Fidler, D.V.M.,Ph.D.

Sue-Hwa Lin,Ph.D.

Christopher J. Logothetis,M.D.

David J. McConkey, Ph.D.

Timothy J. McDonnell,M.D.,Ph.D.

Nora M. Navone,M.D.,Ph.D.

Christos N. Papandreou,M.D.,Ph.D.

Andrew C. von Eschenbach,M.D.

Christopher G. Wood,M.D.

Southwestern Medical Center, Dallas

Jerry W. Shay, Ph.D.

University of Toronto (Canada)

$350,000

Sunnybrook Health Science Center

Shoukat Dedhar, Ph.D.

Robert S. Kerbel,Ph.D.

University of Utah, Health

Sciences Center

$100,000

Arthur R. Brothman,Ph.D.

University of Virginia

$3,650,000

Leland W.K. Chung, Ph.D.

Thomas A.Gardner, M.D.

Deborah Lannigan,Ph.D.

Charles E. Myers,Jr.,M.D.

J. Thomas Parsons,Ph.D.

Fraydoon Rastinejad,Ph.D.

Mitchell Sokoloff,M.D.

Michael J. Weber, Ph.D.

University of Washington

$7,873,220

Arthur Camerman,Ph.D.

Martin A. Cheever, M.D.

Leroy Hood,M.D.,Ph.D.

Gail Jarvik,M.D.,Ph.D.

Paul H.Lange,M.D.

Alvin Liu,Ph.D.

Robert L. Vessella,Ph.D.

University of Wisconsin

$3,875,000

David A. Boothman,Ph.D.

Chawnshang Chang, Ph.D.

David F. Jarrard,M.D.

Douglas G. McNeel,M.D.,Ph.D.

George Wilding, M.D.

Donald T. Witiak,Ph.D.

Urological Sciences

Research Foundation

$100,000

Leonard S. Marks,M.D.

Utah State Cancer Registry

$183,420

Janet Stanford,M.D.

Vanderbilt University

$350,000

Sam Chang, M.D.

Robert Matusik,Ph.D.

Joseph A. Smith,Jr.,M.D.

Veteran’s Administration

$4,622

Patricia Cornett,M.D.

Volcani Center (Israel)

$180,000

Mark Pines,Ph.D.

Walter Reed Army Medical Center

$50,000

David G. McLeod,M.D., J.D.

Washington University

$3,339,166

William J. Catalona,M.D.

Mark L.Day, Ph.D.

Helen Donis-Keller, Ph.D.

Steven F. Dowdy, Ph.D.

Peter A. Humphrey, M.D.,Ph.D.

Jeffrey Milbrandt,M.D.,Ph.D.

Nobuyuki Oyama, M.D.,Ph.D.

Timothy L. Ratliff,Ph.D.

Brian K. Suarez,Ph.D.

Wayne State University

$350,000

Michael L. Cher, M.D.

Keneth V. Honn,Ph.D.

Harper Hospital

J. Edson Pontes,M.D.

Weizmann Institute of Science (Israel)

$1,625,000

Avri Ben-Ze’ev, Ph.D.

Hadassa Degani,Ph.D.

Zelig Eshhar, Ph.D.

Benjamin Geiger, Ph.D.

Yitzhak Koch,Ph.D.

Yoram Salomon,Ph.D.

Rony Seger, Ph.D.

Yechiel Shai,Ph.D

Yosef Shaul,Ph.D.

David Wallach,Ph.D.

Yosef Yarden,Ph.D.

Yehiel Zick,Ph.D.

Yale University

$200,000

Craig M. Crews,Ph.D.

38

Gerald Ford

Jimmy Carter

Ronald Reagan

George H. W. Bush

Bill Clinton

Presidential Board Board of Directors

Michael Milken

Chairman

Prostate Cancer Foundation

Merv Adelson

Chairman

East West Venture Group

James Blair

General Partner

Domain Associates

Helene Brown

Director Community

Applications of Research

University of California,

Los Angeles

S. Ward (Trip) Casscells III,M.D.

John Edward Tyson

Distinguished Professor of

Medicine and Vice President

of Biotechnology

University of Texas HSC

at Houston

David Ederer

Chairman

Ederer Investment Company

Sue Gin

Chairman and Chief

Executive Officer

Flying Food Group, Inc.

The Reverend Rosey Grier

Milken Family Foundation

Andrew Grove

Chairman

Intel Corporation

Stuart Holden,M.D.

Director

Cedars-Sinai Louis

Warschaw Prostate Cancer Center

Warschaw, Robertson, Law Families

Chair in Prostate Cancer

Cedars-Sinai Medical Center

David Koch

Executive Vice President

Koch Industries

Earle Mack

Senior Partner

The Mack Company

Shmuel Meiter

Director

Aurec Group

Lori Milken

Vice President

Prostate Cancer Foundation

Nelson Peltz

Chairman and Chief

Executive Officer

Triarc Companies, Inc.

Lynda Resnick

Vice Chairman

Roll International

Bert Roberts

Consultant

Richard Sandler

Partner, Maron and Sandler

Executive Vice President

Milken Family Foundation

Lorraine Spurge

Managing Director

Metropolitan West Financial

Michael L. Tarnopol

Vice Chairman

Bear, Stearns & Co. Inc.

Robert Voss

President

Fox Packaging Company

Jerry Weintraub

President

Jerry Weintraub Productions

Elaine Wynn

Co-Chief Executive Officer

Wynn Resorts

Stanley Zax

Chairman and President

Zenith National Insurance Corporation

Leadership

39

Executive Officers

Leslie D. Michelson

Vice Chairman and

Chief Executive Officer

Debbie Bohnett

Executive Vice President,

Marketing and Development

Howard Soule, Ph.D.

Executive Vice President

and Chief Science Officer

Stuart Holden,M.D.

Chief Medical Officer

Michael B. Kaiserman

Chief Development Officer

Gregg S. Britt

Senior Vice President,

Biopharmaceutical Research

and Development

Scott Harvey

Senior Vice President,

Corporate Alliances

Jan Haber

Manager, Special Events

Honorary Board

Ken Aretsky

Edward Asner

Anne Bancroft

Warren Beatty

Harry Belafonte

Samuel Belzberg

Metuka Benjamin

Fred Biletnikoff

Pat Boone

Mel Brooks

John S. Chalsty

Tony Coelho

Jim Colbert

Bill Cosby

Jamie B. Coulter

Billy Davis,Jr.

Alan Dershowitz

Sen. Robert Dole

Clint Eastwood

Sen. Dianne Feinstein

Irving Feintech

David Foster

Emil Frei III,M.D.

Howard Gittis

Whoopi Goldberg

Berry Gordy

Robert Goulet

General Alexander Haig

Monty Hall

Alan Hassenfeld

Quincy Jones

Hamilton Jordan

Joseph Kanter

Neal Kassell,M.D.

Sidney Kimmel

Larry King

John W. Kluge

Beth Kobliner

Sandy Koufax

Tommy Lasorda

Tom Laughlin

Norman Lear

Marv Levy

Carl Lindner

Robert Linton

Marilyn McCoo

Lowell Milken

Avram Miller

Jerry Monkarsh

Robert Novak

Arnold Palmer

Claudia Peltz

Sidney Poitier

Charlie Rose

Gen.H. Norman Schwarzkopf

Marvin Shanken

Sen. Brad Sherman

Neil Simon

Sen. Ted Stevens

Louis W. Sullivan,M.D.

Allan Tessler

William H. Tilley

Joe Torre

Clyde Turner

Tracey Ullman

Robert Wagner

Rep. Maxine Waters

Bob Watson

Will Weinstein

Jerry West

Stephen Wynn

Bud Yorkin

40

We Need You

The Prostate Cancer Foundation

welcomes your help and support in

our mission to find better treat-

ments and a cure for adva n ced

pro s t a te cancer.

Three Ways to Donate

Please mail your check to:

Prostate Cancer Foundation

1250 Fourth Street

Santa Monica, California 90401

Make your check payable to

the Prostate Cancer Foundation.

To make an online contribution,

please visit our web site:

www.prostatecancerfoundation.org

To make a credit card donation call

8 0 0 . 7 5 7 . 2 8 7 3 .

Memorial or Tribute Gifts

Honor the memory of a loved one

or celebrate the accomplishment

of a friend or family member by

helping others. Make a memorial or

tribute gift and the PCF will send an

acknowledgement card to the family

of the honoree.

The Pro s t a te Ca n cer Fo u n d a ti on• Funds innova tive re s e a rch that leads to bet ter tre a tm en t s .

• Puts money in researchers’ hands quickly.

• Brings together leading academic scientists with biotech

and pharmaceutical companies and government leaders

and researchers.

• Su pports a con s ortium of the nati on’s leading cancer cen ters .

• Leads public awareness campaigns about prostate cancer.

• Gives men and their families hope for better, longer lives.

Other Gift Suggestions

• Assets or property including

real estate.

• Bequest — include a gift to PCF

in your will.

• Securities.

• Name the PCF as the primary or

contingent beneficiary on a life

insurance policy.

We will be happy to work with you

and your advisors to arrange a gift

that meets the needs of you and

your family. Thank you for your

generous support.

For additional information,please

c a ll us at 800.757.2873 or e-mail us at

info@prostatecancerfoundation.org.

The chart on page 6 inc ludes the most recently reported annual results for the following philanthropies: Alzheimer’s and

Related Disorders Association, American Cancer Society, American Foundation for AIDS Research, American Heart Association,

American Lung Association, Arthritis Foundation, Christopher Reeve Paralysis Foundation, Juvenile Diabetes Research

Foundation, Leukemia and Lymphoma Foundation, March of Dimes, Muscular Dystrophy Association, National Kidney

Foundation, National Multiple Sclerosis Society and Susan G. Komen Breast Cancer Foundation.

1250 Fourth Street

Santa Monica, California 90401

Tel 310.570.4700 Fax 310.570.4701

www.prostatecancerfoundation.org